Jithma P. Abeykoon, M.D.

Contact Us for the Latest Status

• MC220806: Phase I Study Evaluating the Efficacy of CSF1R and TAM Receptor Inhibition in Hematologic Malignancies with Q702, a Small Molecular Inhibitor Rochester, Minn., Scottsdale/Phoenix, Ariz.

  The purpose of this study is establish the highest dose of Q702 tested that has acceptable tolerability and safety.